Cyanidin-3-o-glucoside directly binds to ER&#x03B1;36 and inhibits EGFR-positive triple-negative breast cancer

Li Wang; Haifeng Li; Shiping Yang; Wenqiang Ma; Mei Liu; Shichao Guo; Jun Zhan; Hongquan Zhang; Suk Ying Tsang; Ziding Zhang; Zhaoyi Wang; Xiru Li; Yang-Dong Guo; Xiangdong Li

doi:10.18632/oncotarget.12025

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Cyanidin-3-o-glucoside directly binds to ERα36 and inhibits EGFR-positive triple-negative breast cancer

Li Wang, Haifeng Li, Shiping Yang, Wenqiang Ma, Mei Liu, Shichao Guo, Jun Zhan, Hongquan Zhang, Suk Ying Tsang, Ziding Zhang, Zhaoyi Wang, Xiru Li, Yang-Dong Guo _ and Xiangdong Li

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:68864-68882. https://doi.org/10.18632/oncotarget.12025

Metrics: PDF 2224 views | HTML 3464 views | ?

Abstract

Li Wang1,*, Haifeng Li1,*, Shiping Yang1, Wenqiang Ma1, Mei Liu2, Shichao Guo1, Jun Zhan3, Hongquan Zhang3, Suk Ying Tsang4, Ziding Zhang1, Zhaoyi Wang5, Xiru Li2, Yang-Dong Guo1, Xiangdong Li1

1State Key Laboratory of the Agro-Biotechnology, College of Horticultural Science, China Agricultural University, Beijing, China

2Department of General Surgery, The 301th Hospital of PLA, Beijing, China

3Key Laboratory of Carcinogenesis and Translational Research, Ministry of Education, State Key Laboratory of Natural and Biomimetic Drugs, Peking University Health Science Center, Beijing, China

4School of Life Sciences and State Key Laboratory of Agro-Biotechnology, Chinese University of Hong Kong, Hong Kong, China

5Beijing Shenogen Pharma Group, Beijing, China

*These authors have contributed equally to this work

Correspondence to:

Yang-Dong Guo, email: [email protected]

Xiru Li, email: [email protected]

Zhaoyi Wang, email: [email protected]

Xiangdong Li, email: [email protected]

Keywords: Cy-3-glu, ERα36, EGFR, triple-negative breast cancer, apoptosis

Received: December 03, 2015 Accepted: September 02, 2016 Published: September 15, 2016

ABSTRACT

Anthocyanins have been shown to inhibit the growth and metastatic potential of breast cancer (BC) cells. However, the effects of individual anthocyanins on triple-negative breast cancer (TNBC) have not yet been studied. In this study, we found that cyanidin-3-o-glucoside (Cy-3-glu) preferentially promotes the apoptosis of TNBC cells, which co-express the estrogen receptor alpha 36 (ERα36) and the epidermal growth factor receptor (EGFR). We demonstrated that Cy-3-glu directly binds to the ligand-binding domain (LBD) of ERα36, inhibits EGFR/AKT signaling, and promotes EGFR degradation. We also confirmed the therapeutic efficacy of Cy-3-glu on TNBC in the xenograft mouse model. Our data indicates that Cy-3-glu could be a novel preventive/therapeutic agent against the TNBC co-expressed ERα36/EGFR.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12025

Publication Alerts

Research Papers:

Cyanidin-3-o-glucoside directly binds to ERα36 and inhibits EGFR-positive triple-negative breast cancer

Abstract